Mefruside

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 525610

CAS#: 7195-27-9

Description: Mefruside is a diuretic indicated for the treatment of edema and hypertension.

Chemical Structure

img
Mefruside
CAS# 7195-27-9
Instruction

Theoretical Analysis

MedKoo Cat#: 525610
Name: Mefruside
CAS#: 7195-27-9
Chemical Formula: C13H19ClN2O5S2
Exact Mass: 382.04
Molecular Weight: 382.874
Elemental Analysis: C, 40.78; H, 5.00; Cl, 9.26; N, 7.32; O, 20.89; S, 16.75

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: FDA1902; FDA-1902; FDA 1902; FBA 1500; FBA-1500; FBA1500; Mefrusida; Mefrusidum; Mefrusal; Mefrusid; Mefruside

IUPAC/Chemical Name: 4-chloro-N1-methyl-N1-((2-methyltetrahydrofuran-2-yl)methyl)benzene-1,3-disulfonamide

InChi Key: SMNOERSLNYGGOU-UHFFFAOYSA-N

InChi Code: InChI=1S/C13H19ClN2O5S2/c1-13(6-3-7-21-13)9-16(2)23(19,20)10-4-5-11(14)12(8-10)22(15,17)18/h4-5,8H,3,6-7,9H2,1-2H3,(H2,15,17,18)

SMILES Code: O=S(C1=CC=C(Cl)C(S(=O)(N)=O)=C1)(N(C)CC2(C)OCCC2)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 382.87 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: el Walily AF. Simultaneous determination of the binary mixture of nifedipine and mefruside using derivate spectroscopy, capillary gas-liquid chromatography and high performance liquid chromatography. Acta Pharm Hung. 1997 Mar-May;67(2-3):89-97. PubMed PMID: 9223759.
2: Landmark K, Forsman M, Lindberg K, Ryman T, Martmann-Moe K, Haaverstad S, Wiel S. Nitrendipine and mefruside in elderly hypertensives: effects on blood pressure, cardiac output, cerebral blood flow and metabolic parameters. J Hum Hypertens. 1995 Apr;9(4):281-5. PubMed PMID: 7595911.
3: Höfling B, Häringer E, Herrmann W, Pieske H, Pieske R, Philippi M. [Therapy of mild to moderate hypertension. Efficacy and tolerance of Amlodipine in comparison with the combination nifedipine/mefruside]. Fortschr Med. 1991 May 20;109(15):327-30. German. PubMed PMID: 1830287.
4: Kirsten R, Heller A, Heintz B, Nelson K. Influence of co-dergocrine mesilate/nifedipine compared to mefruside/nifedipine on circadian blood pressure in patients with essential hypertension. J Hum Hypertens. 1990 Aug;4(4):461-4. PubMed PMID: 2258894.
5: Notghi A, Anderton JL. Effect of nifedipine and mefruside on renal reserve in hypertensive patients. Postgrad Med J. 1988 Nov;64(757):856-9. PubMed PMID: 3255934; PubMed Central PMCID: PMC2429038.
6: Schulte KL, Meyer-Sabellek W, Röcker L, Gotzen R, Distler A. Effects of diltiazem alone and combined with mefruside on cardiovascular response at rest and during exercise, carbohydrate metabolism and serum lipoproteins in patients with systemic hypertension. Am J Cardiol. 1987 Oct 1;60(10):826-31. PubMed PMID: 3661396.
7: Saito F, Kimura G, Shimozaki Y, Fujii T, Ishii T, Yoshida K, Abe H, Kawamura M, Deguchi F, Kawano Y, et al. [Mechanism of hypotensive action of a diuretic, mefruside, based on the pressure-natriuresis relationship]. Nihon Jinzo Gakkai Shi. 1987 Apr;29(4):461-7. Japanese. PubMed PMID: 3656703.
8: Notghi A, Fiskerstrand CE, Burnet ME, Anderton JL. Effect of nifedipine and mefruside on renal function and platelet function in hypertensive patients. Curr Med Res Opin. 1987;10(7):441-9. PubMed PMID: 3621989.
9: Poulter N, Thompson AV, Sever PS. A double-blind, placebo-controlled, crossover trial to investigate the additive hypotensive effect of a diuretic (mefruside) to that produced by nifedipine. J Cardiovasc Pharmacol. 1987;10 Suppl 10:S53-6. PubMed PMID: 2455140.
10: Junginger HE, Wedler M. Thermal stability of mefruside-polyvinylpyrrolidone solid dispersions. Pharm Res. 1986 Feb;3(1):41-4. doi: 10.1023/A:1016320831469. PubMed PMID: 24271355.
11: Buemi M, Macrì I, Ussi F, Frisina N. [A new guanabenz-mefruside drug in the treatment of arterial hypertension]. Minerva Cardioangiol. 1985 Jan-Feb;33(1-2):73-80. Italian. PubMed PMID: 4010975.
12: Schulte KL, Meyer-Sabellek W, Gotzen R. Effects of acebutolol combined with mefruside on total-body and serum potassium in essential hypertensive patients. Int J Clin Pharmacol Ther Toxicol. 1984 Aug;22(8):438-40. PubMed PMID: 6490227.
13: Douglas-Jones AP, Mitchell AD. Comparison of nifedipine (retard formulation) and mefruside in the treatment of mild to moderate hypertension--a prospective randomized double-blind crossover study in general practice. Postgrad Med J. 1984 Aug;60(706):529-32. PubMed PMID: 6382224; PubMed Central PMCID: PMC2417958.
14: Tomasi AM, Pirani R, Masoni C. [Treatment of idiopathic hypertension with guanabenz-mefruside]. Minerva Cardioangiol. 1984 May;32(5):339-44. Italian. PubMed PMID: 6382059.
15: Frisina N, Macrì I, Ussi F. [Treatment of arterial hypertension with a new drug combining guanabenz-mefruside]. Minerva Cardioangiol. 1984 May;32(5):325-32. Italian. PubMed PMID: 6382057.
16: Fleuren HL, Verwey-Van Wissen CP, Van Rossum JM. Quantitative gas chromatographic determination of two oxidized metabolites of the diuretic mefruside in human urine, plasma and red blood cells. J Chromatogr. 1980 May 9;182(2):179-90. PubMed PMID: 7380910.
17: Henningsen NC, Bergengren B, Malmborg O, Pihl O, Renmarker K, Strand L. Effects of mefruside treatment in hypertension. Acta Med Scand. 1980;208(4):272-8. PubMed PMID: 7446207.
18: Seedat YK. An evaluation of debrisoquine and mefruside in the treatment of hypertension in African and Indian patients. Curr Med Res Opin. 1980;7(1):68-72. PubMed PMID: 7428417.
19: Fleuren HL, Verwey-van Wissen CP, van Rossum JM. Pharmacokinetics of mefruside and two active metabolites in man. Eur J Clin Pharmacol. 1980 Jan;17(1):59-69. PubMed PMID: 7371701.
20: Fleuren HL, Verwey-van Wissen CP, van Rossum JM. Quantitative gas chromatographic determination of mefruside in body fluids by extractive methylation and nitrogen detection. Arzneimittelforschung. 1979;29(7):1041-7. PubMed PMID: 582996.